Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients : CD47 expression is a favourable prognostic factor
Copyright © 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved..
Myeloid sarcoma is a rare extramedullary haematopoietic malignancy. Interaction between CD47 and signal regulatory protein α (SIRPα) inhibits phagocytosis. CD47-positive tumours confer poor prognoses in various malignant tumours, including acute myeloid leukaemia. This study aimed to investigate the clinicopathological effects of CD47 and SIRPα expression in myeloid sarcoma. Immunohistochemistry (IHC) of CD47 and SIRPα was performed in 84 biopsy samples obtained from patients with myeloid sarcoma, some of which were CD47-positive. Patients were categorised into the following two groups based on IHC of SIRPα: those with SIRPα-positive neoplastic cells (nSIRPα) and, SIRPα expression on non-neoplastic stromal cells in tumour microenvironment (miSIRPα). In addition, patients with CD47 positivity had higher lymphocytic infiltration into the tumour microenvironment. Overall, these patients had significantly higher overall survival, however, no significant difference was observed in progression-free survival. No significant prognostic differences were observed between the nSIRPα and miSIRPα groups. This is the first study to demonstrate an association between CD47 expression and improved prognosis in myeloid sarcoma. Nonetheless, it will be necessary to conduct additional research on gene expression and genomic abnormalities to elucidate the corresponding pathogenesis of myeloid sarcoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Pathology - 56(2024), 1 vom: 20. Jan., Seite 81-91 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tanaka, Ken [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukaemia |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pathol.2023.10.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366010190 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366010190 | ||
| 003 | DE-627 | ||
| 005 | 20240124232023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pathol.2023.10.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM366010190 | ||
| 035 | |a (NLM)38110323 | ||
| 035 | |a (PII)S0031-3025(23)00302-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tanaka, Ken |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients |b CD47 expression is a favourable prognostic factor |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Myeloid sarcoma is a rare extramedullary haematopoietic malignancy. Interaction between CD47 and signal regulatory protein α (SIRPα) inhibits phagocytosis. CD47-positive tumours confer poor prognoses in various malignant tumours, including acute myeloid leukaemia. This study aimed to investigate the clinicopathological effects of CD47 and SIRPα expression in myeloid sarcoma. Immunohistochemistry (IHC) of CD47 and SIRPα was performed in 84 biopsy samples obtained from patients with myeloid sarcoma, some of which were CD47-positive. Patients were categorised into the following two groups based on IHC of SIRPα: those with SIRPα-positive neoplastic cells (nSIRPα) and, SIRPα expression on non-neoplastic stromal cells in tumour microenvironment (miSIRPα). In addition, patients with CD47 positivity had higher lymphocytic infiltration into the tumour microenvironment. Overall, these patients had significantly higher overall survival, however, no significant difference was observed in progression-free survival. No significant prognostic differences were observed between the nSIRPα and miSIRPα groups. This is the first study to demonstrate an association between CD47 expression and improved prognosis in myeloid sarcoma. Nonetheless, it will be necessary to conduct additional research on gene expression and genomic abnormalities to elucidate the corresponding pathogenesis of myeloid sarcoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD47 | |
| 650 | 4 | |a Myeloid sarcoma | |
| 650 | 4 | |a acute myeloid leukaemia | |
| 650 | 4 | |a signal regulatory protein α | |
| 650 | 7 | |a Receptors, Immunologic |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation |2 NLM | |
| 650 | 7 | |a CD47 Antigen |2 NLM | |
| 650 | 7 | |a CD47 protein, human |2 NLM | |
| 700 | 1 | |a Miyoshi, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamoto, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Shimasaki, Yasumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Imamoto, Teppei |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Kyohei |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Moritsubo, Mayuko |e verfasserin |4 aut | |
| 700 | 1 | |a Furuta, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Kohno, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Sonoki, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohshima, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathology |d 1969 |g 56(2024), 1 vom: 20. Jan., Seite 81-91 |w (DE-627)NLM000008656 |x 1465-3931 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:81-91 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pathol.2023.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2024 |e 1 |b 20 |c 01 |h 81-91 | ||